Ionis Pharmaceuticals INC Form 4 insider transactions

EVP Kyle Jenne acquired 12,226 shares via RSU vesting and sold 4,902 shares to cover tax obligations.

EVP Brian Birchler acquired 1,875 shares via RSU vesting and sold 973 shares to cover tax obligations.

EVP and Chief Business Officer Joseph Baroldi reported the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Ionis Pharmaceuticals Director Joseph Klein III reported transactions involving the sale of company stock, executed under a Rule 10b5-1 trading plan.

Shannon L. Devers, EVP and Chief Human Resources Officer at Ionis Pharmaceuticals, Inc., has sold 6,193 shares of common stock for approximately $74.05 per share, as part of a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer Eugene Schneider sold 5,812 shares of common stock for approximately $70.97 per share.

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and sold common stock on March 3 and 4, 2026, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph Klein III exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Ionis Pharmaceuticals Director Allene M. Diaz exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, sold 20,106 shares of common stock on March 3, 2026, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, and his spouse sold company common stock totaling over $531,000 through pre-arranged trading plans.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, acquired 256 shares of common stock through an employee stock purchase plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, acquired 376 shares of common stock through an employee stock purchase plan.

Ionis Pharmaceuticals CEO Brett Monia acquired 484 shares of common stock through an employee stock purchase plan at $48.8665 per share.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, filed an amended Form 4 to correct and reverse previously reported erroneous stock sales and option exercises.

Ionis Pharmaceuticals' EVP of Research, Eric Swayze, sold 15,642 shares of common stock on February 13, 2026, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock for approximately $82.72 per share under a pre-arranged trading plan.

Ionis Pharmaceuticals CEO Brett P. Monia sold 29,430 shares of common stock for approximately $2.5 million under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, executed a series of stock option exercises and subsequent sales of common stock totaling 85,089 shares under a pre-arranged 10b5-1 plan.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, reported the vesting of performance-based restricted stock units and a subsequent sale of common stock.

Ionis Pharmaceuticals' EVP and Chief Clinical Development Officer, Eugene Schneider, acquired shares from performance-based restricted stock units and subsequently sold a portion of his holdings.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, acquired shares from performance-based restricted stock unit vesting and subsequently sold a portion of his holdings.

Ionis Pharmaceuticals CEO Brett P. Monia reported the vesting of performance-based restricted stock units and subsequent sale of common stock.

Ionis Pharmaceuticals' EVP, Finance & CFO, Elizabeth L. Hougen, acquired shares from vested performance-based restricted stock units and subsequently sold a portion of her common stock.

Ionis Pharmaceuticals EVP Brian Birchler acquired shares from performance-based vesting and subsequently sold a portion of his common stock holdings.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, acquired 11,421 shares from vested performance-based restricted stock units and subsequently sold 5,885 shares.

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, sold 5,296 shares of common stock after vesting of performance-based restricted stock units.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer Shannon L. Devers, sold 3,977 shares of common stock for approximately $81.34 per share under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director Michael J. Yang acquired 1,930 shares of common stock through the vesting of Restricted Stock Units.